157 related articles for article (PubMed ID: 11212325)
21. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis.
Canu N; Barbato C; Ciotti MT; Serafino A; Dus L; Calissano P
J Neurosci; 2000 Jan; 20(2):589-99. PubMed ID: 10632588
[TBL] [Abstract][Full Text] [Related]
22. A new structural class of proteasome inhibitors that prevent NF-kappa B activation.
Lum RT; Kerwar SS; Meyer SM; Nelson MG; Schow SR; Shiffman D; Wick MM; Joly A
Biochem Pharmacol; 1998 May; 55(9):1391-7. PubMed ID: 10076530
[TBL] [Abstract][Full Text] [Related]
23. Stabilization of p53 by adenovirus E1A occurs through its amino-terminal region by modification of the ubiquitin-proteasome pathway.
Nakajima T; Morita K; Tsunoda H; Imajoh-Ohmi S; Tanaka H; Yasuda H; Oda K
J Biol Chem; 1998 Aug; 273(32):20036-45. PubMed ID: 9685342
[TBL] [Abstract][Full Text] [Related]
24. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.
Schubert U; Antón LC; Bacík I; Cox JH; Bour S; Bennink JR; Orlowski M; Strebel K; Yewdell JW
J Virol; 1998 Mar; 72(3):2280-8. PubMed ID: 9499087
[TBL] [Abstract][Full Text] [Related]
25. The ubiquitin-proteasome pathway and proteasome inhibitors.
Myung J; Kim KB; Crews CM
Med Res Rev; 2001 Jul; 21(4):245-73. PubMed ID: 11410931
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor alpha induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kappaB: abrogation of the tumor necrosis factor alpha effect by proteasome inhibitors.
Sakai T; Kambe F; Mitsuyama H; Ishiguro N; Kurokouchi K; Takigawa M; Iwata H; Seo H
J Bone Miner Res; 2001 Jul; 16(7):1272-80. PubMed ID: 11450703
[TBL] [Abstract][Full Text] [Related]
27. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation.
Parcellier A; Schmitt E; Gurbuxani S; Seigneurin-Berny D; Pance A; Chantôme A; Plenchette S; Khochbin S; Solary E; Garrido C
Mol Cell Biol; 2003 Aug; 23(16):5790-802. PubMed ID: 12897149
[TBL] [Abstract][Full Text] [Related]
28. In vivo ubiquitination and proteasome-mediated degradation of p53(1).
Maki CG; Huibregtse JM; Howley PM
Cancer Res; 1996 Jun; 56(11):2649-54. PubMed ID: 8653711
[TBL] [Abstract][Full Text] [Related]
29. Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest.
Hu X; Bryington M; Fisher AB; Liang X; Zhang X; Cui D; Datta I; Zuckerman KS
J Biol Chem; 2002 May; 277(19):16528-37. PubMed ID: 11864973
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibitors induce inhibitory kappa B (I kappa B) kinase activation, I kappa B alpha degradation, and nuclear factor kappa B activation in HT-29 cells.
Németh ZH; Wong HR; Odoms K; Deitch EA; Szabó C; Vizi ES; Haskó G
Mol Pharmacol; 2004 Feb; 65(2):342-9. PubMed ID: 14742676
[TBL] [Abstract][Full Text] [Related]
31. Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway.
Whitehouse AS; Khal J; Tisdale MJ
Br J Cancer; 2003 Aug; 89(4):737-45. PubMed ID: 12915888
[TBL] [Abstract][Full Text] [Related]
32. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
[TBL] [Abstract][Full Text] [Related]
33. Protein degradation by proteasomes: molecular mechanisms of muscle catabolism.
Mitch WE; Price SR
Nephrol Dial Transplant; 1997 Jan; 12(1):13-5. PubMed ID: 9027764
[No Abstract] [Full Text] [Related]
34. Ubiquitin-proteasome pathway as a primary defender against TRAIL-mediated cell death.
Kim S; Choi K; Kwon D; Benveniste EN; Choi C
Cell Mol Life Sci; 2004 May; 61(9):1075-81. PubMed ID: 15112054
[TBL] [Abstract][Full Text] [Related]
35. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
36. Bcl-2 activates the transcription factor NFkappaB through the degradation of the cytoplasmic inhibitor IkappaBalpha.
de Moissac D; Mustapha S; Greenberg AH; Kirshenbaum LA
J Biol Chem; 1998 Sep; 273(37):23946-51. PubMed ID: 9727009
[TBL] [Abstract][Full Text] [Related]
37. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes.
Masdehors P; Merle-Béral H; Maloum K; Omura S; Magdelénat H; Delic J
Blood; 2000 Jul; 96(1):269-74. PubMed ID: 10891461
[TBL] [Abstract][Full Text] [Related]
38. Proteasomes as drug targets.
Piccinini M; Mostert M; Rinaudo MT
Curr Drug Targets; 2003 Nov; 4(8):657-71. PubMed ID: 14577657
[TBL] [Abstract][Full Text] [Related]
39. Protein degradation and apoptotic death in lymphocytes during Fiv infection: activation of the ubiquitin-proteasome proteolytic system.
Piedimonte G; Crinelli R; Della Salda L; Corsi D; Pennisi MG; Kramer L; Casabianca A; Sarli G; Bendinelli M; Marcato PS; Magnani M
Exp Cell Res; 1999 May; 248(2):381-90. PubMed ID: 10222130
[TBL] [Abstract][Full Text] [Related]
40. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation.
Desterro JM; Rodriguez MS; Hay RT
Mol Cell; 1998 Aug; 2(2):233-9. PubMed ID: 9734360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
